| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA547: Tofacitinib for moderately to severely active ulcerative colitis |
|
Medicine details |
|
| Medicine name | tofacitinib (Xeljanz®) |
| Formulation | 10 mg film-coated tablet |
| Reference number | 1573 |
| Indication | Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent |
| Company | Pfizer Ltd |
| BNF chapter | Gastro-intestinal system |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 27/06/2018 |
| NICE guidance | TA547: Tofacitinib for moderately to severely active ulcerative colitis |